Mediators of Inflammation

Research Article

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

Table 1

Clinical characteristics of our patients with pulmonary sarcoidosis and healthy controls.


	Healthy controls	Sarcoidosis
	Healthy controls	With LS (CXR 1)	Without LS (CXR 3)

Gender, men/women	2/11	8/4	6/6
Mean age (min–max)	45.6 (23–62)	45.5 (32–62)	46.6 (26–72)
Smoking history (nonsmoker/ex-/current smoker/NA)	13/0/0/0	9/1/1/1	9/2/1/0
CXR stage 0/1	NA	12	NA
CXR stage 3/4	NA	NA	10/2
FEV1 (min–max) (%)	NA	106 (99–109)	90 (59–113)
FEV1/VC (min–max) (%)	NA	81 (69–90)	76 (74–80)
Mean DLCO (min–max) (%)	NA	101 (82–131)	78 (46–98)
Mean DLCO/VA (min–max) (%)	NA	90 (84–94)	103 (95–115)

NA, not available or not applicable; CXR, chest X-ray; LS, Löfgren’s syndrome; DLCO, diffusing capacity of the lung for carbon monoxide; VA, alveolar volume and a nonsmoker was defined as a never smoker and an ex-smoker was defined as someone who has not been smoking for at least 2 years before serum collection. FEV1, forced expiratory volume in 1 second; VC, vital capacity.